Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
961.71B
Market cap961.71B
Price-Earnings ratio
45.14
Price-Earnings ratio45.14
Dividend yield
0.58%
Dividend yield0.58%
Average volume
4.41M
Average volume4.41M
High today
$1,047.35
High today$1,047.35
Low today
$1,014.00
Low today$1,014.00
Open price
$1,032.00
Open price$1,032.00
Volume
1.31M
Volume1.31M
52 Week high
$1,133.95
52 Week high$1,133.95
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

With a market cap of 961.71B, Eli Lilly(LLY) trades at $1,019.42. The stock has a price-to-earnings ratio of 45.14 and currently yields dividends of 57.9%.

On 2026-02-18, Eli Lilly(LLY) stock moved within a range of $1,014.00 to $1,047.35. With shares now at $1,019.42, the stock is trading +0.5% above its intraday low and -2.7% below the session's peak.

Trading volume for Eli Lilly(LLY) stock has reached 1.31M, versus its average volume of 4.41M.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,133.95 and a low of $623.78.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,133.95 and a low of $623.78.

LLY News

TipRanks 2h
Eli Lilly Stock in Focus as Zepbound Found to Help Treat Psoriasis

Eli Lilly’s (LLY) stock is back in focus on reports that its weight-loss drug Zepbound can help to treat skin conditions such as psoriasis. A late-stage study...

Simply Wall St 17h
Eli Lilly Readies Orforglipron As Broader Pipeline Shapes Valuation Story

Eli Lilly (NYSE:LLY) is preparing for the launch of its oral weight loss pill Orforglipron, backing it with large inventory build up and new manufacturing inves...

Eli Lilly Readies Orforglipron As Broader Pipeline Shapes Valuation Story
Investor's Business Daily 22h
Long-Term Care Provider Soars In Base, Approaches Buy Point

Halozyme, Other Hot Medical Plays Lead 22 Stocks Onto Best Stock Lists Like IBD 50, IPO Leaders 2/05/2026 See which stocks like medical plays Halozyme and Eli...

Long-Term Care Provider Soars In Base, Approaches Buy Point

Analyst ratings

78%

of 32 ratings
Buy
78.1%
Hold
18.8%
Sell
3.1%

More LLY News

TipRanks 1d
Eli Lilly Stock Rises on Plan to Invest $1 Billion in India

The stock of Eli Lilly (LLY) is up about 1% after the pharmaceutical company announced plans to invest $1 billion in India as part of its global expansion. Spe...

TipRanks 1d
Eli Lilly looks to turn India into hub for global supply chain, Reuters says

Eli Lilly (LLY) intends to turn India into a hub for its global supply chain, Rishika Sadam and Kashish Tandon of Reuters reports, citing comments made by a sen...

24/7 Wall St. 2d
Why Eli Lilly's $1 Billion AI Bet Could Reshape Drug Discovery

Why Eli Lilly’s $1 Billion AI Bet Could Reshape Drug Discovery Quick Read Eli Lilly (LLY) reported Q4 EPS of $7.54 versus $6.67 expected. Eli Lilly projected 2...

Why Eli Lilly's $1 Billion AI Bet Could Reshape Drug Discovery
TipRanks 2d
Eli Lilly Builds $1.5 Billion Inventory of Weight-Loss Pill

Eli Lilly (LLY) has built $1.5 billion worth of pre-launch inventory of Orforglipron, the company’s new weight-loss pill. The inventory build-up comes as Eli L...

TipRanks 2d
Eli Lilly reports Phase 3 LIBRETTO-432 study of Retevmo met primary endpoint

Eli Lilly (LLY) announced topline results from the Phase 3 LIBRETTO-432 clinical trial of Retevmo as adjuvant therapy versus placebo. The study met its primary...

The Motley Fool 4d
What Is One of the Best Pharmaceutical Stocks to Own for the Next 10 Years?

Eli Lilly continues to pursue smart acquisitions for the long term. The pharmaceutical industry can be a tricky investment. Remember Pfizer (PFE +0.38%) back i...

What Is One of the Best Pharmaceutical Stocks to Own for the Next 10 Years?
Simply Wall St 5d
How Lilly’s GLP-1 Momentum, Orforglipron Launch and Orna Deal Could Shape Eli Lilly Investors

Eli Lilly recently reported past fourth-quarter 2025 and full-year results showing higher sales and net income, issued 2026 revenue guidance of US$80.00 billion...

How Lilly’s GLP-1 Momentum, Orforglipron Launch and Orna Deal Could Shape Eli Lilly Investors

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.